20 / 37
Page 54
conferenceseries
.com
Volume 6
Journal of Child & Adolescent Behavior
October 01-02, 2018 Osaka, Japan
30
th
World
Psychiatrists and Psychologists Meet
World Psychiatrists 2018
October 01-02, 2018
Effect of thyroxin treatment on carotid intima-media thickness reduction in patients with subclinical
hypothyroidism: A meta-analysis of clinical trials
Aziz M
1,2
, Kandimalla Y
3
, Machavarapu A
3
, Saxena A
1
, Das S
1
, Younus A
1
, Nguyen M
3
, Malik R
1
, Anugula D
5
, Latif M A
1
, Humayun C
1
, Khan I M
1
, Adus
A
1
, Rasool A
1
, Veledar E
1
and Nasir K
1,5,6
1
Baptist Health South Florida, USA
2
Benedictine University, USA
3
Ocala Regional Medical Center, USA
4
Creighton University Medical Center, USA
5
Florida International University, USA
6
Johns Hopkins University, USA
Aim:
Research shows that Subclinical Hypothyroidism (SCH) is related to an increased Carotid Intima-Media Thickness
(CIMT), a surrogate marker of subclinical Cardiovascular Disease (CVD). It is controversial whether or not SCH should be
treated to reduce CVD morbidity and mortality. This meta-analysis aimed to determine whether SCH is associated with an
increase in CIMT as compared to Euthyroidism (EU) and whetherThyroxin (T4) treatment in SCH can reverse the change in CIMT.
Methods:
Two independent reviewers conducted an extensive database research up to December 2016. A total of 12 clinical
trials discussed the effect of Thyroxin on CIMT values at pre and post-treatment in subjects with SCH.
Results:
CIMT was significantly higher among SCH (n=280) as compared to EU controls (n=263) at baseline; the pooled
Weighted Mean Difference (WMD) of CIMT was 0.44 mm [95% confidence interval (CI) 0.14, 0.74], p=0.004; I2=65%. After
treatment with thyroxin in subjects with SCH (n=314), there was a statistically significant decrease in CIMT from pre- to
post-treatment; the pooled WMD of CIMT decrease was [WMD-0.32; 95% CI (-0.47, -0.16), p=<0.0001; I2=2%], and it was
no longer different from EU controls [WMD 0.13 mm; 95% CI (-0.04, 0.30); p=0.14; I2=27%]. The total cholesterol (TC),
triglycerides (TG) and Low-Density Lipoprotein (LDL) were higher in SCH as compared to EU controls and decreased
significantly after treatment with thyroxin.
Conclusion:
This meta-analysis shows that thyroxin therapy in subjects with SCH significantly decreases CIMT and improves
lipid profile, modifiable CVD risk factors. Thyroid hormone replacement in subjects with SCHmay play a role in slowing down
or preventing the progression of atherosclerosis.
satisht817@gmail.comJ Child Adolesc Behav 2018, Volume 6
DOI: 10.4172/2375-4494-C1-006